Elodie Persyn

Elodie Persyn

Auto-generated profile, based on publicly available information

Elodie Persyn

Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
EPElodie Persyn
Elodie Persyn
KHKen B. Hanscombe
Ken B. Hanscombe
JHJoanna M. M. Howson
Joanna M. M. Howson
CLCathryn Lewis
Cathryn Lewis
MTMatthew Traylor
Matthew Traylor
HMHugh S. Markus
Hugh S. Markus
Cerebral small vessel disease is a major cause of stroke and dementia, but its genetic basis is incompletely understood. We perform a genetic study of three MRI markers of the disease in UK Biobank imaging data and other sources: white matter hyperintensities (N = 42,310), fractional anisotropy (N = 17,663) and mean diffusivity (N = 17,467). Our aim is to better understand the disease pathophysiology. Across the three traits, we identify 31 loci, of which 21 were previously unreported. We perform a transcriptome-wide association study to identify associations with gene expression in relevant tissues, identifying 66 associated genes across the three traits. This genetic study provides insights into the understanding of the biological mechanisms underlying small vessel disease.

29 March 2023 in Nature
Verified
Journal Article
Closed access
PDF file
YXYu Xu
Yu Xu
SRScott C. Ritchie
Scott C. Ritchie
YLYujian Liang
Yujian Liang
PTPaul Reimund Hugo Jan Timmers
Paul Reimund Hugo Jan Timmers
MPMaik Pietzner
Maik Pietzner
MIMichael Inouye
Michael Inouye

17 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLingyan Chen
Lingyan Chen
JPJames E. Peters
James E. Peters
BPBram Peter Prins
Bram Peter Prins
EPElodie Persyn
Elodie Persyn
MTMatthew Traylor
Matthew Traylor
JHJoanna M. M. Howson
Joanna M. M. Howson
Stroke is the second leading cause of death with substantial unmet therapeutic needs. To identify potential stroke therapeutic targets, we estimate the causal effects of 308 plasma proteins on stroke outcomes in a two-sample Mendelian randomization framework and assess mediation effects by stroke risk factors. We find associations between genetically predicted plasma levels of six proteins and stroke (P ≤ 1.62 × 10−4). The genetic associations with stroke colocalize (Posterior Probability >0.7) with the genetic associations of four proteins (TFPI, TMPRSS5, CD6, CD40). Mendelian randomization supports atrial fibrillation, body mass index, smoking, blood pressure, white matter hyperintensities and type 2 diabetes as stroke risk factors (P ≤ 0.0071). Body mass index, white matter hyperintensity and atrial fibrillation appear to mediate the TFPI, IL6RA, TMPRSS5 associations with stroke. Furthermore, thirty-six proteins are associated with one or more of these risk factors using Mendelian randomization. Our results highlight causal pathways and potential therapeutic targets for stroke.

3 February 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SSSolena Le Scouarnec
Solena Le Scouarnec
MKMatilde Karakachoff
Matilde Karakachoff
JGJean-Baptiste Gourraud
Jean-Baptiste Gourraud
PLPierre Lindenbaum
Pierre Lindenbaum
SBStéphanie Bonnaud
Stéphanie Bonnaud
RRRichard Redon
Richard Redon
The Brugada syndrome (BrS) is a rare heritable cardiac arrhythmia disorder associated with ventricular fibrillation and sudden cardiac death. Mutations in the SCN5A gene have been causally related to BrS in 20–30% of cases. Twenty other genes have been described as involved in BrS, but their overall contribution to disease prevalence is still unclear. This study aims to estimate the burden of rare coding variation in arrhythmia-susceptibility genes among a large group of patients with BrS. We have developed a custom kit to capture and sequence the coding regions of 45 previously reported arrhythmia-susceptibility genes and applied this kit to 167 index cases presenting with a Brugada pattern on the electrocardiogram as well as 167 individuals aged over 65-year old and showing no history of cardiac arrhythmia. By applying burden tests, a significant enrichment in rare coding variation (with a minor allele frequency below 0.1%) was observed only for SCN5A, with rare coding variants carried by 20.4% of cases with BrS versus 2.4% of control individuals (P = 1.4 × 10−7). No significant enrichment was observed for any other arrhythmia-susceptibility gene, including SCN10A and CACNA1C. These results indicate that, except for SCN5A, rare coding variation in previously reported arrhythmia-susceptibility genes do not contribute significantly to the occurrence of BrS in a population with European ancestry. Extreme caution should thus be taken when interpreting genetic variation in molecular diagnostic setting, since rare coding variants were observed in a similar extent among cases versus controls, for most previously reported BrS-susceptibility genes.

6 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EPElodie Persyn
Elodie Persyn
RRRichard Redon
Richard Redon
LBLise Bellanger
Lise Bellanger
CDChristian Dina
Christian Dina
Population stratification is a well-known confounding factor in both common and rare variant association analyses. Rare variants tend to be more geographically clustered than common variants, because of their more recent origin. However, it is not yet clear if population stratification at a very fine scale (neighboring administrative regions within a country) would lead to statistical bias in rare variant analyses. As the inclusion of convenience controls from external studies is indeed a common procedure, in order to increase the power to detect genetic associations, this problem is important. We studied through simulation the impact of a fine scale population structure on different rare variant association strategies, assessing type I error and power. We showed that principal component analysis (PCA) based methods of adjustment for population stratification adequately corrected type I error inflation at the largest geographical scales, but not at finest scales. We also showed in our simulations that adding controls obviously increased power, but at a considerably lower level when controls were drawn from another population.

4 March 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ATAlex Tokolyi
Alex Tokolyi
EPElodie Persyn
Elodie Persyn
ANArtika P. Nath
Artika P. Nath
KBKatie L. Burnham
Katie L. Burnham
JMJonathan Marten
Jonathan Marten
DPDirk S. Paul
Dirk S. Paul
The biological mechanisms through which most nonprotein-coding genetic variants affect disease risk are unknown. To investigate gene-regulatory mechanisms, we mapped blood gene expression and splicing quantitative trait loci (QTLs) through bulk RNA sequencing in 4,732 participants and integrated protein, metabolite and lipid data from the same individuals. We identified cis -QTLs for the expression of 17,233 genes and 29,514 splicing events (in 6,853 genes). Colocalization analyses revealed 3,430 proteomic and metabolomic traits with a shared association signal with either gene expression or splicing. We quantified the relative contribution of the genetic effects at loci with shared etiology, observing 222 molecular phenotypes significantly mediated by gene expression or splicing. We uncovered gene-regulatory mechanisms at disease loci with therapeutic implications, such as WARS1 in hypertension, IL7R in dermatitis and IFNAR2 in COVID-19. Our study provides an open-access resource on the shared genetic etiology across transcriptional phenotypes, molecular traits and health outcomes in humans ( https://IntervalRNA.org.uk ).